JP5759722B2 - アダリムマブの結合蛋白質を含む組成物及び方法 - Google Patents
アダリムマブの結合蛋白質を含む組成物及び方法 Download PDFInfo
- Publication number
- JP5759722B2 JP5759722B2 JP2010522939A JP2010522939A JP5759722B2 JP 5759722 B2 JP5759722 B2 JP 5759722B2 JP 2010522939 A JP2010522939 A JP 2010522939A JP 2010522939 A JP2010522939 A JP 2010522939A JP 5759722 B2 JP5759722 B2 JP 5759722B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- adalimumab
- antigen
- antibodies
- hybridoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Description
アダリムマブをペプシン又はパパインで消化した後、プロテインAカラムを使用して精製し、夫々F(ab)2及びFabフラグメントを作製した。アダリムマブフラグメントの純度と生物活性を夫々SDS−PAGE及びL929細胞傷害性バイオアッセイにより確認した。次にBalb/cマウスをアダリムマブフラグメントで順次免疫した。各免疫/ブースター後に採取した血清をELISAにより分析した。正常ヒトIgGよりもアダリムマブに対する力価の高いマウスをATCCから入手したFOミエローマ細胞との融合に選択した。選択したマウスに由来する脾臓を使用してマウスハイブリドーマを作製した。ディファレンシャルELISAによりアダリムマブと特異的に結合する抗体についてハイブリドーマ上清をスクリーニングした。96ウェルプレートにアダリムマブ又は正常ヒトIgG 5μg/mLをコーティングした。ハイブリドーマ上清を加え、結合した抗体を西洋ワサビペルオキシダーゼで標識したヤギ抗マウスIgG抗体により検出した。アダリムマブをコーティングしたプレートに対して陽性反応を示し、ヒトIgGをコーティングしたプレートに対して陰性反応を示した上清を更に10倍、30倍及び100倍の希釈倍率で希釈し、親和性ランキングについて再試験した。アダリムマブに対して強い結合を示す抗体を分泌したハイブリドーマをサブクローニングした。サブクローンをELISAにより再びスクリーニングし、数個のモノクローナル抗体を得た。
5A1−2A8はモノクローナルマウスIgG1κ軽鎖抗体である。アダリムマブとヒトIgGをコーティングしたプレートで5A1−2A8抗体産生ハイブリドーマの上清を数種の希釈倍率で試験した。各希釈倍率で5A1−2A8はアダリムマブをコーティングしたプレートに結合したが、ヒトIgGをコーティングしたプレートには結合しなかった(表1)。ヒトTNFが5A1−2A8とアダリムマブの結合を阻害するか否かを試験するために、上清の各希釈液をヒトTNF 100μg/mLと混合した後にELISAでアダリムマブをコーティングしたプレートに加えた。各希釈倍率でTNFを反応混合物に加えたが、5A1−2A8とアダリムマブの結合はさほど阻害されなかった(表1)。従って、5A1−2A8は非パラトープ抗イディオタイプ抗アダリムマブ抗体であるということができる。TNFがアダリムマブ抗体と結合しているか否かに拘わらず、この抗体はアダリムマブと結合することができる。
1H11−2E10はモノクローナルマウスIgG1κ軽鎖抗体である。アダリムマブ及びヒトIgGをコーティングしたプレートで1H11−2E10抗体産生ハイブリドーマの上清を数種類の希釈倍率で試験した。各希釈倍率で1H11−2E10はアダリムマブをコーティングしたプレートに結合したが、ヒトIgGをコーティングしたプレートには結合しなかった(表4)。ヒトTNFが1H11−2E10とアダリムマブの結合を阻害するか否かを試験するために、各希釈倍率の上清をヒトTNF 100μg/mLと混合後、ELISAでアダリムマブをコーティングしたプレートに加えた。各希釈倍率でTNFを反応混合物に加えると、1H11−2E10とアダリムマブの結合は阻害された(表4)。従って、1H11−2E10はパラトープ抗イディオタイプ抗アダリムマブ抗体であるということができる。この抗体は遊離アダリムマブと結合することができるが、TNF結合アダリムマブとは結合することができない。
未結合型TNFは他のサイトカインと同様にインビボ半減期が短い。サイトカインが他の蛋白質(特に抗体)と結合すると、これらのサイトカイン:抗体免疫複合体は未結合型サイトカインよりも半減期が長くなる。従って、抗体を投与した対象では、サイトカインが絶えず産生される場合にサイトカイン:抗体複合体のレベルは増加する。持続的にTNFを産生する患者を同定することが重要である。例えば本発明のモノクローナル抗体5A1−2A8は非パラトープ抗イディオタイプ抗アダリムマブ抗体であるので、TNF:アダリムマブ免疫複合体を検出するためにELISAフォーマットで使用することができる。更に、5A1−2A8はアダリムマブがTNFを含まないか否かに関係なく、アダリムマブを測定するために使用することができる(他方、1H11−2E10はTNFを含まない場合にしかアダリムマブを測定するために使用することができない)。アダリムマブ以外の別のエピトープでTNFと結合する抗ヒトTNF抗体を使用してプレート(例えば96ウェルプレート)のウェルをコーティングできるようにELISAを構成することができる。ウェルをブロック後、TNF:アダリムマブ複合体を含むサンプルを加え、アダリムマブに対する標識抗体(例えばビオチン化5A1−2A8モノクローナル抗体)によりアダリムマブを検出することができる。表7はこのようなアッセイのデータを示す。
Claims (15)
- ATCCアクセション番号PTA−8513を有するハイブリドーマにより産生される5A1−2A8若しくはATCCアクセション番号PTA−8512を有するハイブリドーマにより産生される1H11−2E10のいずれかである単離モノクローナル抗体又はその抗原結合部分。
- Fabフラグメント又は1本鎖抗体である請求項1に記載の抗体又はその抗原結合部分。
- アダリムマブと特異的に結合するモノクローナル抗体を産生するハイブリドーマ細胞株であって、前記ハイブリドーマ細胞株がATCCアクセション番号PTA−8512又はPTA−8513を有する前記ハイブリドーマ細胞株。
- 請求項1に記載の前記抗体又はその抗原結合部分と治療剤を含む免疫複合体。
- 前記治療剤がステロイド性抗炎症薬、非ステロイド性抗炎症薬及びDMARDから構成される群から選択される抗炎症薬である請求項4に記載の免疫複合体。
- 請求項4に記載の前記免疫複合体と医薬的に許容可能なキャリヤーを含有する医薬組成物。
- サンプル中のアダリムマブの検出方法であって、抗体−抗原複合体形成に適した条件下で請求項1に記載の抗体又はその抗原結合部分と前記サンプルを接触させた後に前記複合体形成を検出する段階を含む前記方法。
- 前記抗体又はその抗原結合部分がATCCアクセション番号PTA−8513を有するハイブリドーマにより産生される5A1−2A8である請求項7に記載の方法。
- 前記抗体又はその抗原結合部分がATCCアクセション番号PTA−8512を有するハイブリドーマにより産生される1H11−2E10である請求項7に記載の方法。
- EIA、ELISA、RIA、間接競合イムノアッセイ、直接競合イムノアッセイ、非競合イムノアッセイ、サンドイッチイムノアッセイ及び凝集アッセイから構成される群から選択される手段により前記検出を実施する請求項7に記載の方法。
- 1種以上の抗アダリムマブ抗体又はその抗原結合部分と、抗体−抗原複合体を助長するために必要な試薬を含むキットであって、前記1種以上の抗アダリムマブ抗体がATCCアクセション番号PTA−8513を有するハイブリドーマにより産生される5A1−2A8若しくはATCCアクセション番号PTA−8512を有するハイブリドーマにより産生される1H11−2E10のいずれかである、前記キット。
- 更に前記1種以上の抗アダリムマブ抗体と特異的に相互作用するエピトープをもつ実質的に単離されたポリペプチドを含む請求項11に記載のキット。
- 更に対照抗体を含み、前記対照抗体がアダリムマブ又はそのフラグメントと反応しない請求項11に記載のキット。
- 前記1種以上の抗アダリムマブ抗体がATCCアクセション番号PTA−8513を有するハイブリドーマにより産生される5A1−2A8である請求項11に記載のキット。
- 前記1種以上の抗アダリムマブ抗体がATCCアクセション番号PTA−8512を有するハイブリドーマにより産生される1H11−2E10である請求項11に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96641007P | 2007-08-28 | 2007-08-28 | |
US60/966,410 | 2007-08-28 | ||
PCT/US2008/010154 WO2009032128A1 (en) | 2007-08-28 | 2008-08-27 | Compositions and methods comprising binding proteins for adalimumab |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014040333A Division JP2014139198A (ja) | 2007-08-28 | 2014-03-03 | アダリムマブの結合蛋白質を含む組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010537983A JP2010537983A (ja) | 2010-12-09 |
JP5759722B2 true JP5759722B2 (ja) | 2015-08-05 |
Family
ID=40429181
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010522939A Expired - Fee Related JP5759722B2 (ja) | 2007-08-28 | 2008-08-27 | アダリムマブの結合蛋白質を含む組成物及び方法 |
JP2014040333A Pending JP2014139198A (ja) | 2007-08-28 | 2014-03-03 | アダリムマブの結合蛋白質を含む組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014040333A Pending JP2014139198A (ja) | 2007-08-28 | 2014-03-03 | アダリムマブの結合蛋白質を含む組成物及び方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8969024B2 (ja) |
EP (1) | EP2193145A4 (ja) |
JP (2) | JP5759722B2 (ja) |
CN (1) | CN101802005B (ja) |
CA (1) | CA2696210A1 (ja) |
MX (1) | MX2010002269A (ja) |
WO (1) | WO2009032128A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
CA2898009C (en) | 2005-05-16 | 2018-03-27 | Rebecca S. Hoffman | Use of tnfa inhibitor for treatment of erosive polyarthritis |
RS53055B (en) | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
NZ571479A (en) | 2006-04-05 | 2012-10-26 | Abbott Biotech Ltd | Antibody purification |
EP2012586A4 (en) | 2006-04-10 | 2010-08-18 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS |
US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
NZ613356A (en) | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
RU2010107994A (ru) * | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
US8969024B2 (en) * | 2007-08-28 | 2015-03-03 | Abbvie Biotechnology Ltd | Compositions and methods comprising binding proteins for adalimumab |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
PT2575884T (pt) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Utilizações e composições para o tratamento de hidradenite supurativa (hs) |
CN103458926B (zh) | 2010-11-11 | 2016-10-26 | 艾伯维生物技术有限公司 | 改进的高浓度抗TNF α 抗体液体制剂 |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
WO2014026905A1 (en) | 2012-08-17 | 2014-02-20 | Morphosys Ag | Complex-specific antibodies and antibody fragments and its use |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
HUE032569T2 (en) * | 2012-09-19 | 2017-09-28 | Abbvie Biotherapeutics Inc | A method for identifying antibodies with reduced immunogenicity |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
EP3066469B1 (en) | 2013-11-05 | 2017-10-11 | Roche Diagnostics GmbH | A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
SE538541C2 (en) | 2015-01-19 | 2016-09-13 | Fogelstrand Per | Method for preparing a biological sample for use in an immunolabeling process |
IL260750B2 (en) * | 2016-03-04 | 2024-02-01 | Morphosys Ag | Clinical evaluation of protein-M response in multiple myeloma |
CN117054645A (zh) | 2016-09-06 | 2023-11-14 | 富士瑞必欧株式会社 | 甲状腺球蛋白的测定方法及测定试剂 |
EP3514539A4 (en) | 2016-09-13 | 2020-04-01 | Fujirebio Inc. | TEST PROCEDURE AND TEST REAGENT FOR HEART TROPONIN |
CN108535490A (zh) * | 2017-03-06 | 2018-09-14 | 苏州和锐生物科技有限公司 | 生物制剂血药浓度检测方法及试剂 |
EP3514541A1 (de) * | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors |
JPWO2020241443A1 (ja) | 2019-05-24 | 2020-12-03 | ||
CN114514427A (zh) | 2019-09-27 | 2022-05-17 | 富士瑞必欧株式会社 | 乙型肝炎病毒核心相关抗原的免疫测定和用于其的试剂盒 |
WO2021139720A1 (zh) * | 2020-01-08 | 2021-07-15 | 信达生物制药(苏州)有限公司 | 阿达木单抗纯化方法及其稳定组合物 |
US20230160912A1 (en) | 2020-03-31 | 2023-05-25 | Fujirebio Inc. | Method for immunoassay of amyloid beta in blood, and kit for same |
CN117616277A (zh) | 2021-08-06 | 2024-02-27 | 株式会社先端生命科学研究所 | 甲状腺球蛋白的免疫检测及用于其的试剂盒 |
CN117003870B (zh) * | 2023-10-07 | 2023-12-12 | 北京丹大生物技术有限公司 | 一种用于检测阿达木单抗的杂交瘤细胞株组合和抗体组合及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04507285A (ja) * | 1988-12-09 | 1992-12-17 | セントコー・インコーポレーテッド | 抗イディオトープ免疫検定法 |
WO1992008495A1 (en) * | 1990-11-09 | 1992-05-29 | Abbott Biotech, Inc. | Cytokine immunoconjugates |
GB2279077B (en) | 1990-12-21 | 1995-06-14 | Celltech Ltd | Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha |
DE69231828T3 (de) | 1991-03-18 | 2008-06-19 | New York University | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
IT1254315B (it) | 1992-03-27 | 1995-09-14 | Mini Ricerca Scient Tecnolog | Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf. |
DE122009000074I1 (de) | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
US5858361A (en) * | 1993-05-27 | 1999-01-12 | Wagner; Uwe | Monoclonal anti-idiotypic anti-CA125 antibodies and pharmaceutical compositions containing them |
AU1437195A (en) * | 1993-12-20 | 1995-07-10 | Regents Of The University Of California, The | Methods for the production and use of anti-idiotypic antibodies using human ig expressing transgenic animals |
US5665558A (en) * | 1994-05-17 | 1997-09-09 | Gamma Biologicals, Inc. | Method and apparatus useful for detecting bloodgroup antigens and antibodies |
CU22585A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
BRPI9707379C8 (pt) * | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
AU9024198A (en) * | 1997-08-19 | 1999-03-08 | Vanderbilt University | Methods for determining cell responses through ephb receptors |
US6838250B2 (en) * | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
AU2005241431A1 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
US20060266532A1 (en) * | 2005-05-24 | 2006-11-30 | Ansul Canada Limited | Multi-drive converter unit for driving multiple fire suppression accessories |
US20060286108A1 (en) * | 2005-06-16 | 2006-12-21 | Bell Katherine A | Topical compositions for the treatment of chronic wounds |
JPWO2007023782A1 (ja) * | 2005-08-24 | 2009-02-26 | 株式会社ジーンケア研究所 | キラートキシン様タンパク質に対する中和抗体、およびその利用 |
RS53055B (en) * | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
EP1917854A1 (en) * | 2006-11-06 | 2008-05-07 | F. Hoffmann-La Roche Ag | Method for producing anti idiotypic antibodies |
US7985965B2 (en) * | 2007-03-29 | 2011-07-26 | Raytheon Company | Quantum computing device and method including qubit arrays of entangled states using negative refractive index lenses |
US8969024B2 (en) * | 2007-08-28 | 2015-03-03 | Abbvie Biotechnology Ltd | Compositions and methods comprising binding proteins for adalimumab |
-
2008
- 2008-08-27 US US12/229,788 patent/US8969024B2/en active Active
- 2008-08-27 JP JP2010522939A patent/JP5759722B2/ja not_active Expired - Fee Related
- 2008-08-27 CN CN200880104516.3A patent/CN101802005B/zh not_active Expired - Fee Related
- 2008-08-27 MX MX2010002269A patent/MX2010002269A/es active IP Right Grant
- 2008-08-27 EP EP08829709A patent/EP2193145A4/en not_active Withdrawn
- 2008-08-27 WO PCT/US2008/010154 patent/WO2009032128A1/en active Application Filing
- 2008-08-27 CA CA2696210A patent/CA2696210A1/en not_active Abandoned
-
2014
- 2014-03-03 JP JP2014040333A patent/JP2014139198A/ja active Pending
-
2015
- 2015-02-24 US US14/630,322 patent/US9321846B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20150166678A1 (en) | 2015-06-18 |
EP2193145A1 (en) | 2010-06-09 |
US20090068172A1 (en) | 2009-03-12 |
CA2696210A1 (en) | 2009-03-12 |
JP2010537983A (ja) | 2010-12-09 |
CN101802005A (zh) | 2010-08-11 |
US8969024B2 (en) | 2015-03-03 |
CN101802005B (zh) | 2015-09-16 |
WO2009032128A1 (en) | 2009-03-12 |
MX2010002269A (es) | 2010-03-25 |
JP2014139198A (ja) | 2014-07-31 |
EP2193145A4 (en) | 2011-05-18 |
US9321846B2 (en) | 2016-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5759722B2 (ja) | アダリムマブの結合蛋白質を含む組成物及び方法 | |
RU2766094C2 (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
US8071729B2 (en) | Anti-integrin antibodies, compositions, methods and uses | |
JP5014557B2 (ja) | 抗−デュアルインテグリン抗体(anti−dualintegrinantibodies)、組成物、方法及び使用 | |
AU2006236417B2 (en) | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | |
PT2423230E (pt) | Membro de ligação para o recetor de gm-csf | |
AU2004237766B2 (en) | CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses. | |
KR20150008080A (ko) | 항-cd22 항체 | |
JP2022137167A (ja) | 活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法 | |
AU2020243588A1 (en) | Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody | |
US7479479B2 (en) | CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses | |
KR20220113346A (ko) | 칸디다에 대한 항체 및 이의 용도 | |
JP2023524668A (ja) | 若年性特発性関節炎を治療するための材料及び方法 | |
WO2021220140A1 (en) | Materials and methods for treating juvenile idiopathic arthritis | |
JP2022536279A (ja) | 乾癬性関節炎を治療するための抗tnf抗体組成物及び方法 | |
AU2021315081A1 (en) | Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110825 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131127 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20131127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131204 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5759722 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |